Back to Search
Start Over
Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study
- Publication Year :
- 2018
-
Abstract
- Aim: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. Methods: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. Results: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1–87) months. Patients were divided into three groups according to the duration of GNRH analogues use; 4–12 months (Group A), 13–24 months (Group B) and ≥25 months (Group C). Overall, 530 patients were analyzed; 23.2%, 45.8%, 30.9% of the patients were in Group A, B and C, respectively. The median follow-up duration was 34 ± 30.3 (range, 4–188) months. The OS in patients ≤35 years of age was found to be significantly longer than that of patients >35 years of age in Group B (log rank, P = 0.023). The disease-free survival of the patients in Group A was significantly shorter than that of patients in Group C (log rank, P = 0.003). The OS of Group A patients was significantly shorter in comparison to that of Group B and Group C patients (log rank, P = 0.000) and the OS of Group B patients was significantly shorter than Group C (log rank, P = 0,000). Conclusion: There is currently no definite data on the optimal duration of GnRH analogues use. One of the important results of this study that will provide an insight to the future studies is the improvement gained in OS by the increase in the duration of GnRH analogues use. © 2017 John Wiley & Sons Australia, Ltd
- Subjects :
- Oncology
cancer patient
demography
Adult
Breast Neoplasms/*drug therapy/mortality
Disease-Free Survival
Female
Gonadotropin-Releasing Hormone/pharmacology/*therapeutic use
Humans
Medical Oncology
Middle Aged
Retrospective Studies
Young Adult
retrospective study
medicine.medical_treatment
gonadorelin associated peptide derivative
Group A
Turkey (republic)
Group B
fluorouracil
Gonadotropin-Releasing Hormone
0302 clinical medicine
middle aged
docetaxel
030212 general & internal medicine
cancer survival
disease free survival
tamoxifen
breast tumor
adult
adjuvant therapy
hormone sensitivity
General Medicine
Hormone-sensitive
trastuzumab
female
priority journal
early cancer
030220 oncology & carcinogenesis
oncology
cancer grading
young adult
Adjuvant
hormones, hormone substitutes, and hormone antagonists
pharmacy
medicine.medical_specialty
endocrine system
overall survival
premenopause
Breast Neoplasms
anthracycline
Article
multiple cycle treatment
03 medical and health sciences
breast cancer
Breast cancer
Internal medicine
medicine
follow up
controlled study
human
survival time
Gonadotropin-releasing hormone analogue
treatment duration
business.industry
medicine.disease
major clinical study
mortality
Log-rank test
gonadorelin
aromatase inhibitor
cyclophosphamide
business
Hormone
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....dd1b91e3c54bc9025a04ba27872edb34